ClinicalTrials.gg
CompletedNCT02184741Updated Jan 28, 2022

A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage

A Phase 3 interventional study of GB-0998 and Placebo in Recurrent Miscarriage, sponsored by Japan Blood Products Organization. Completed at 1 site in Japan. Open to female participants aged Up to 41 Years. Per ClinicalTrials.gov, last updated 2022-01-28.

Sponsored by Japan Blood Products Organization · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
Up to 41 Years
Sex
Female
01

Study summary

The present survey was conducted to evaluate the efficacy and safety of GB-0998(immunoglobulin) in the treatment of unexplained recurrent miscarriage in comparison to placebo using a multicenter, double-blind, intergroup comparison method.

Read the detailed description

Among the patients whose risk factors for recurrent miscarriage are unknown who repeatedly miscarry or patients who repeatedly miscarry despite treatment for risk factors, those who have never given birth and have had four or more miscarriages. Patients were assigned into two groups, GB-0998 or placebo, and received 8 ml/kg body weight of GB-0998 (400 mg/kg body weight) or placebo once a day for 5 days. The primary efficacy endpoint was ongoing pregnancy rate at 22 weeks of gestation (excluding miscarriages associated with fetal chromosomal abnormalities) and one of the secondary endpoint was live birth rate.

02

Conditions studied

  • Recurrent Miscarriage

Browse trials for

Keywords

  • IVIG
  • Unexplained Recurrent miscarriage
  • Primary Recurrent miscarriage
  • Intravenous immunoglobulin
03

In context

Abortion, Habitual

102 studies on the registry are indexed under Abortion, Habitual; 21 are open to participants now.

This study's enrollment of 99 is below the median of 126 across 55 interventional studies indexed under Abortion, Habitual.

Browse Abortion, Habitual studies →

Lead sponsor

Japan Blood Products Organization is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 41 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with primary recurrent miscarriage
  2. Patients with a history of at least 4 miscarriages (not including biochemical pregnancy in the count of prior miscarriages)
  3. Patients with any of the following risk factors for recurrent miscarriage

【Patients with unknown risk factors】 Patients with normal test results for each of the following risk factors who have experienced miscarriage of a fetus with normal chromosome karyotype

  1. Abnormal uterine morphology
  2. Thyroid dysfunction
  3. Chromosome abnormality in the couple
  4. Positive antiphospholipid antibody
  5. Factor XII deficiency
  6. Protein S deficiency
  7. Protein C deficiency

【Patients determined to have risk factors】 Patients with the following risk factors who have experienced miscarriage of a fetus with normal chromosome karyotype despite receiving treatment for these factors

  1. Abnormal uterine morphology (septate uterus): Patients who have undergone surgery
  2. Thyroid dysfunction: Patients receiving medical treatment
  3. Incidentally positive antiphospholipid antibody, factor XII deficiency, protein S deficiency, protein C deficiency:Patients receiving combination therapy with aspirin and heparin 4.Regardless of whether or not risk factors are present, patients should have experienced at least 1 a miscarriage of a fetus with normal chromosome karyotype 5.Patients below the age of 42 years at the time of obtaining 6.Patients who can be admitted for at least the period from the start date of administration of the study drug to the date of examination and assessment 1 week after the start of administration of the study drug 7.Patients who have given written informed consent to participate in this study

Exclusion criteria

Exclusion Criteria:

  1. Patients with chromosome abnormalities in themselves or their partners that are risk factors for recurrent miscarriage, patients with antiphospholipid syndrome, and patients with incidentally positive antiphospholipid antibody (when the latest test result is positive)
  2. Patients in whom complications of diabetes mellitus or impaired glucose tolerance has been identified, but who have not received appropriate treatment for this condition
  3. Patients who have received intravenous immunoglobulin therapy as treatment for recurrent miscarriage in the past
  4. Patients with a history of stillbirth at 22 weeks of gestation or later
  5. Patients receiving treatment for malignant tumor
  6. Patients with a history of thromboembolism
  7. Patients with a history of shock or in response to the ingredients of this drug or patients with hereditary fructose intolerance
  8. Patients who have been diagnosed with IgA deficiency in the past or patients who have a serum IgA level of \<5 mg/dL at laboratory tests at registration
  9. Patients who have received another study drug within the period of 12 weeks prior to or who are currently participating in another clinical trial
  10. Patients who are unsuitable for this study for any other reason, in the opinion of a principal investigator or sub-investigators
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
99 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Infusion of normal saline

    Drug: Placebo

  • Experimental
    GB-0998

    Infusion of GB-0998 (Immunoglobulin)

    Drug: GB-0998

Interventions

  • Subjects received GB-0998 at 400 mg/kg body weight once daily for 5 days until 6 weeks and 6 days of gestation after confirmation of the gestational sac by ultrasonography.

    Also known as: Intravenous Immunoglobulin (Venoglobulin®IH,2.5g/50ml)

  • DrugPlacebo

    Subjects received the same dose of saline as GB-0998 for 5 days after confirmation of the gestational sac by ultrasonography, up to 6 weeks and 6 days of gestation.

    Also known as: normal saline

06

What researchers measure

Primary outcomes

  1. Ongoing pregnancy rate (excluding miscarriages associated with fetal chromosomal abnormalities)

    To evaluate the effectiveness of the drug in preventing miscarriages, we examined the ongoing pregnancy rate at 22 weeks and 0 days of gestation in cases excluding cases of fetal chromosome aberration miscarriages.

    Time frame: At 22 weeks of gestation

Secondary outcomes

  1. Ongoing pregnancy rate(all patients)

    To evaluate the effectiveness of the drug in preventing miscarriages, we examined the ongoing pregnancy rate at 22 weeks and 0 days of gestation in all patients.

    Time frame: At 22 weeks of gestation

  2. Live birth rate (excluding miscarriages associated with fetal chromosomal abnormalities)

    To evaluate the effectiveness of the drug in total outcome of pregnancy, we examined the live birth rate in cases excluding cases of fetal chromosome aberration miscarriages.

    Time frame: At the time of birth

  3. Live birth rate(all patients)

    To evaluate the effectiveness of the drug in total outcome of pregnancy, we examined the live birth rate in all patients.

    Time frame: At the time of birth

07

Study locations

1 site
  • Japan Blood Products Organization
    Tokyo, Japan
08

References and documents

Publications

  • Yamada H, Deguchi M, Saito S, Takeshita T, Mitsui M, Saito T, Nagamatsu T, Takakuwa K, Nakatsuka M, Yoneda S, Egashira K, Tachibana M, Matsubara K, Honda R, Fukui A, Tanaka K, Sengoku K, Endo T, Yata H. Intravenous immunoglobulin treatment in women with four or more recurrent pregnancy losses: A double-blind, randomised, placebo-controlled trial. EClinicalMedicine. 2022 Jun 29;50:101527. doi: 10.1016/j.eclinm.2022.101527. eCollection 2022 Aug. PubMed 35795714 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2014 to primary completion in May 2020, 71 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2014
First posted
Jul 9, 2014
StartActual
Jun 3, 2014
Primary completionActual
May 2020
CompletionActual
Sep 2020
Last update
Jan 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02184741
Lead sponsor
Japan Blood Products Organization
Responsible party
Sponsor
First posted
Jul 9, 2014
Start date
Jun 3, 2014
Primary completion
May 2020
Completion
Sep 2020
Last update
Jan 28, 2022

Study contacts

Hideto Yamada, Director
principal investigator · Center for Recurrent Pregnancy Loss, Teine Keijinkai Hospital
Shigeru Saito, Professor
principal investigator · University of Toyama

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GB-0998

Start the discussion